188 citations
,
October 2014 in “Thyroid” This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.
173 citations
,
July 2012 in “British Journal of Dermatology” This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.